Clinical usefulness of long-term application of fentanyl matrix in chronic non-cancer pain: Improvement of pain and physical and emotional functions

Jaewon Lee, Joon Shik Yoon, Jae Hyup Lee, So Hak Chung, Kyu Yeol Lee, Young Yul Kim, Jong Moon Kim, Min Ho Kong, Ung Gu Kang, Ye Soo Park

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Opioids are recently recommended for those who do not gain adequate pain relief from the use of acetaminophen or nonsteroidal anti-inflammatory drugs. Medical opioids are administered in various routes, and transdermal opioid products that can make up for the weaknesses of the oral or intravenous products have been developed. This study is to evaluate the clinical usefulness of fentanyl matrix in terms of the long-term improvement in pain and physical and mental functions. Methods: This was a multicenter, open, prospective, observational study that was conducted in 54 institutions in Korea. Patients with non-cancerous chronic pain completed questionnaires, and investigators also completed questionnaires. A total of 1,355 subjects participated in this study, and 639 subjects completed the study. Subjects received transdermal fentanyl matrix (12 μg/hr, 25 μg/hr, or 50 μg/hr depending on the patient’s response and demand). Subjects visited at 29 ± 7 days, 85 ± 14 days, and 169 ± 14 days after administration, respectively, to receive drug titration and fill out the questionnaires. The results were analyzed using the intention-to-treat (ITT) analysis, full analysis set (FAS), and per-protocol (PP) analysis. The FAS analysis included only 451 participants; the PP analysis, 160 participants; and the ITT analysis, 1,355 participants. Results: The intensity of pain measured by the Numeric Rating Scale decreased from 7.07 ± 1.78 to 4.93 ± 2.42. The physical assessment score and mental assessment score of the Short-Form Health Survey 12 improved from 28.94 ± 7.23 to 35.90 ± 10.25 and from 35.80 ± 11.76 to 42.52 ± 10.58, respectively. These differences were significant, and all the other indicators also showed improvement. Adverse events with an incidence of ≥ 1% were nausea, dizziness, vomiting, and pruritus. Conclusions: The long-term administration of fentanyl matrix in patients with non-cancerous pain can reduce the intensity of pain and significantly improves activities of daily living and physical and mental capabilities.

Original languageEnglish
Pages (from-to)465-474
Number of pages10
JournalCiOS Clinics in Orthopedic Surgery
Volume8
Issue number4
DOIs
Publication statusPublished - 2016 Dec 1

Fingerprint

Fentanyl
Pain
Opioid Analgesics
Intention to Treat Analysis
Dizziness
Pruritus
Korea
Acetaminophen
Activities of Daily Living
Health Surveys
Chronic Pain
Pharmaceutical Preparations
Nausea
Vomiting
Observational Studies
Anti-Inflammatory Agents
Research Personnel
Prospective Studies
Incidence
Surveys and Questionnaires

Keywords

  • Chronic non-cancer pain
  • Emotional functioning
  • Fentanyl matrix
  • Physical functioning

ASJC Scopus subject areas

  • Surgery
  • Orthopedics and Sports Medicine

Cite this

Clinical usefulness of long-term application of fentanyl matrix in chronic non-cancer pain : Improvement of pain and physical and emotional functions. / Lee, Jaewon; Yoon, Joon Shik; Lee, Jae Hyup; Chung, So Hak; Lee, Kyu Yeol; Kim, Young Yul; Kim, Jong Moon; Kong, Min Ho; Kang, Ung Gu; Park, Ye Soo.

In: CiOS Clinics in Orthopedic Surgery, Vol. 8, No. 4, 01.12.2016, p. 465-474.

Research output: Contribution to journalArticle

Lee, Jaewon ; Yoon, Joon Shik ; Lee, Jae Hyup ; Chung, So Hak ; Lee, Kyu Yeol ; Kim, Young Yul ; Kim, Jong Moon ; Kong, Min Ho ; Kang, Ung Gu ; Park, Ye Soo. / Clinical usefulness of long-term application of fentanyl matrix in chronic non-cancer pain : Improvement of pain and physical and emotional functions. In: CiOS Clinics in Orthopedic Surgery. 2016 ; Vol. 8, No. 4. pp. 465-474.
@article{a038c155d2334d4ebdedcff38913c72b,
title = "Clinical usefulness of long-term application of fentanyl matrix in chronic non-cancer pain: Improvement of pain and physical and emotional functions",
abstract = "Background: Opioids are recently recommended for those who do not gain adequate pain relief from the use of acetaminophen or nonsteroidal anti-inflammatory drugs. Medical opioids are administered in various routes, and transdermal opioid products that can make up for the weaknesses of the oral or intravenous products have been developed. This study is to evaluate the clinical usefulness of fentanyl matrix in terms of the long-term improvement in pain and physical and mental functions. Methods: This was a multicenter, open, prospective, observational study that was conducted in 54 institutions in Korea. Patients with non-cancerous chronic pain completed questionnaires, and investigators also completed questionnaires. A total of 1,355 subjects participated in this study, and 639 subjects completed the study. Subjects received transdermal fentanyl matrix (12 μg/hr, 25 μg/hr, or 50 μg/hr depending on the patient’s response and demand). Subjects visited at 29 ± 7 days, 85 ± 14 days, and 169 ± 14 days after administration, respectively, to receive drug titration and fill out the questionnaires. The results were analyzed using the intention-to-treat (ITT) analysis, full analysis set (FAS), and per-protocol (PP) analysis. The FAS analysis included only 451 participants; the PP analysis, 160 participants; and the ITT analysis, 1,355 participants. Results: The intensity of pain measured by the Numeric Rating Scale decreased from 7.07 ± 1.78 to 4.93 ± 2.42. The physical assessment score and mental assessment score of the Short-Form Health Survey 12 improved from 28.94 ± 7.23 to 35.90 ± 10.25 and from 35.80 ± 11.76 to 42.52 ± 10.58, respectively. These differences were significant, and all the other indicators also showed improvement. Adverse events with an incidence of ≥ 1{\%} were nausea, dizziness, vomiting, and pruritus. Conclusions: The long-term administration of fentanyl matrix in patients with non-cancerous pain can reduce the intensity of pain and significantly improves activities of daily living and physical and mental capabilities.",
keywords = "Chronic non-cancer pain, Emotional functioning, Fentanyl matrix, Physical functioning",
author = "Jaewon Lee and Yoon, {Joon Shik} and Lee, {Jae Hyup} and Chung, {So Hak} and Lee, {Kyu Yeol} and Kim, {Young Yul} and Kim, {Jong Moon} and Kong, {Min Ho} and Kang, {Ung Gu} and Park, {Ye Soo}",
year = "2016",
month = "12",
day = "1",
doi = "10.4055/cios.2016.8.4.465",
language = "English",
volume = "8",
pages = "465--474",
journal = "Clinics in Orthopedic Surgery",
issn = "2005-291X",
publisher = "Korean Orthopaedic Association",
number = "4",

}

TY - JOUR

T1 - Clinical usefulness of long-term application of fentanyl matrix in chronic non-cancer pain

T2 - Improvement of pain and physical and emotional functions

AU - Lee, Jaewon

AU - Yoon, Joon Shik

AU - Lee, Jae Hyup

AU - Chung, So Hak

AU - Lee, Kyu Yeol

AU - Kim, Young Yul

AU - Kim, Jong Moon

AU - Kong, Min Ho

AU - Kang, Ung Gu

AU - Park, Ye Soo

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Background: Opioids are recently recommended for those who do not gain adequate pain relief from the use of acetaminophen or nonsteroidal anti-inflammatory drugs. Medical opioids are administered in various routes, and transdermal opioid products that can make up for the weaknesses of the oral or intravenous products have been developed. This study is to evaluate the clinical usefulness of fentanyl matrix in terms of the long-term improvement in pain and physical and mental functions. Methods: This was a multicenter, open, prospective, observational study that was conducted in 54 institutions in Korea. Patients with non-cancerous chronic pain completed questionnaires, and investigators also completed questionnaires. A total of 1,355 subjects participated in this study, and 639 subjects completed the study. Subjects received transdermal fentanyl matrix (12 μg/hr, 25 μg/hr, or 50 μg/hr depending on the patient’s response and demand). Subjects visited at 29 ± 7 days, 85 ± 14 days, and 169 ± 14 days after administration, respectively, to receive drug titration and fill out the questionnaires. The results were analyzed using the intention-to-treat (ITT) analysis, full analysis set (FAS), and per-protocol (PP) analysis. The FAS analysis included only 451 participants; the PP analysis, 160 participants; and the ITT analysis, 1,355 participants. Results: The intensity of pain measured by the Numeric Rating Scale decreased from 7.07 ± 1.78 to 4.93 ± 2.42. The physical assessment score and mental assessment score of the Short-Form Health Survey 12 improved from 28.94 ± 7.23 to 35.90 ± 10.25 and from 35.80 ± 11.76 to 42.52 ± 10.58, respectively. These differences were significant, and all the other indicators also showed improvement. Adverse events with an incidence of ≥ 1% were nausea, dizziness, vomiting, and pruritus. Conclusions: The long-term administration of fentanyl matrix in patients with non-cancerous pain can reduce the intensity of pain and significantly improves activities of daily living and physical and mental capabilities.

AB - Background: Opioids are recently recommended for those who do not gain adequate pain relief from the use of acetaminophen or nonsteroidal anti-inflammatory drugs. Medical opioids are administered in various routes, and transdermal opioid products that can make up for the weaknesses of the oral or intravenous products have been developed. This study is to evaluate the clinical usefulness of fentanyl matrix in terms of the long-term improvement in pain and physical and mental functions. Methods: This was a multicenter, open, prospective, observational study that was conducted in 54 institutions in Korea. Patients with non-cancerous chronic pain completed questionnaires, and investigators also completed questionnaires. A total of 1,355 subjects participated in this study, and 639 subjects completed the study. Subjects received transdermal fentanyl matrix (12 μg/hr, 25 μg/hr, or 50 μg/hr depending on the patient’s response and demand). Subjects visited at 29 ± 7 days, 85 ± 14 days, and 169 ± 14 days after administration, respectively, to receive drug titration and fill out the questionnaires. The results were analyzed using the intention-to-treat (ITT) analysis, full analysis set (FAS), and per-protocol (PP) analysis. The FAS analysis included only 451 participants; the PP analysis, 160 participants; and the ITT analysis, 1,355 participants. Results: The intensity of pain measured by the Numeric Rating Scale decreased from 7.07 ± 1.78 to 4.93 ± 2.42. The physical assessment score and mental assessment score of the Short-Form Health Survey 12 improved from 28.94 ± 7.23 to 35.90 ± 10.25 and from 35.80 ± 11.76 to 42.52 ± 10.58, respectively. These differences were significant, and all the other indicators also showed improvement. Adverse events with an incidence of ≥ 1% were nausea, dizziness, vomiting, and pruritus. Conclusions: The long-term administration of fentanyl matrix in patients with non-cancerous pain can reduce the intensity of pain and significantly improves activities of daily living and physical and mental capabilities.

KW - Chronic non-cancer pain

KW - Emotional functioning

KW - Fentanyl matrix

KW - Physical functioning

UR - http://www.scopus.com/inward/record.url?scp=84995622163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995622163&partnerID=8YFLogxK

U2 - 10.4055/cios.2016.8.4.465

DO - 10.4055/cios.2016.8.4.465

M3 - Article

C2 - 27904731

AN - SCOPUS:84995622163

VL - 8

SP - 465

EP - 474

JO - Clinics in Orthopedic Surgery

JF - Clinics in Orthopedic Surgery

SN - 2005-291X

IS - 4

ER -